Enzo Biochem

354 articles with Enzo Biochem

• Enzo Biochem Reports Second Quarter Fiscal Year 2023 Financial Results

  3/21/2023

  Enzo Biochem, Inc. (NYSE:ENZ), a pioneering biosciences and diagnostics company, filed its Form 10-Q for the second quarter ended January 31, 2023 of Fiscal Year 2023.

• Enzo Biochem Agrees to Sell Clinical Laboratory to Labcorp

  3/16/2023

  Enzo Biochem, Inc. announced that it has entered into an agreement for Labcorp to acquire the assets of Enzo’s Clinical Laboratory division.

• Enzo Biochem Reports First Quarter Fiscal Year 2023 Financial Results and Provides Business Update

  12/12/2022

  Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today reported operating results for the first quarter ended October 31, 2022 of Fiscal Year 2023 (Q1 FY23) and provided a business update on recent corporate and operational developments.

• Enzo Biochem, Inc. to Report First Quarter Fiscal 2023 Financial Results and Business Update on Monday, December 12th

  12/7/2022

  Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report first quarter fiscal 2023 financial and operating results after the market close on Monday, December 12, 2022.

• Enzo Biochem, Inc. Announces Date of Annual Shareholders’ Meeting

  11/8/2022

  Enzo Biochem, Inc., a leading biosciences and diagnostics company, announced that its Annual Shareholders’ Meeting will be held on January 31, 2023.

• Enzo Biochem, Inc. Appoints Patricia Eckert, CPA as Interim CFO- David Bench resigning to pursue a new career opportunity -

  10/20/2022

  Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced the appointment of Patricia Eckert, CPA, as interim Chief Financial Officer (CFO). 

• Enzo Biochem Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update

  10/14/2022

  Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today reported operating results for the fiscal year and fourth quarter ended July 31, 2022 and provided a business update on recent corporate and operational developments.

• Enzo Biochem to Report Fourth Quarter 2022 Financial Results and Business Update on Friday, October 14th

  10/10/2022

  Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report fourth quarter 2022 financial results on Friday, October 14, 2022, premarket.

• 

  Amgen, Enzo BioChem and Amphista Therapeutics Open New Facilities (Updated)

  10/7/2022

  Amgen opened a new research and development site in San Francisco Bay, while Enzo Biochem opened a 100,000 square foot laboratory and research facility in New York

• Enzo Biochem, Inc. Opens Expanded Life Sciences Laboratory and Office Facilities in Farmingdale, New York

  10/6/2022

  Enzo Biochem, Inc., a leading biosciences and diagnostics company, announced the official launch of the Company’s new 100,000 square foot state-of-the-art laboratory and research facilities in Farmingdale, New York.

• Enzo Biochem, Inc. Launches AMPIVIEW™ Gene Expression Platform with First Products Targeting Detection of HPV and SARS-CoV-2

  9/26/2022

  Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced the launch of the AMPIVIEWs™ line, a breakthrough RNA gene expression platform powered by Enzo’s LoopRNA™ in situ hybridization technology.

• Enzo Biochem to Launch Monkeypox Testing Services this Week

  8/11/2022

  Enzo Biochem, Inc., a leading biosciences and diagnostics company, announced that its full-service clinical laboratory will begin accepting specimens for monkeypox testing this week.

• 

  BioSpace Movers & Shakers: Altos Labs, Vektor, Nautilus, Nurix & More 

  8/5/2022

  New chief executive officers take the reins of companies, while chief financial officers step into their roles overseeing the finances of respective businesses and more. 

• Enzo Biochem Appoints Matthew Kupferberg as General Counsel

  8/3/2022

  Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced the addition of Matthew Kupferberg as the Company’s in-house General Counsel.

• Enzo Biochem Reports Third Quarter Fiscal 2022 Results and Provides Leadership and Corporate Updates Including Engagement of Jefferies as Financial Advisor

  6/9/2022

  Enzo Biochem, Inc (NYSE: ENZ), a leading biosciences and diagnostics company, today reported financial results for the third fiscal quarter ended April 30, 2022, and provided a business update on recent corporate and operational developments.

• UPDATE -- Enzo Biochem to Report Third Quarter 2022 Financial Results and Business Update on Thursday, June 9th Conference Call and Webcast Scheduled for June 10, 2022, 8:30 am ET

  6/6/2022

  Enzo Biochem, Inc., a leading biosciences and diagnostics company, announced that it will report third quarter 2022 financial results on Thursday, June 9, 2022, after the market close.

• Enzo Biochem to Report Third Quarter 2022 Financial Results and Business Update on Thursday, June 9th

  6/2/2022

  Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report third quarter 2022 financial results on Thursday, June 9, 2022, after the market close.

• Enzo Biochem Announces New York State Department of Health Approval of HPV Molecular Diagnostic Test Approval adds HPV to menu of tests available on Enzo’s GenFlex® platform, which includes COVID-19 PCR and CT/NG/TV

  4/19/2022

  Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, announced that it has received approval from the New York State Department of Health (DOH) for its AMPIPROBE® HPV test.

• Enzo Biochem Reports Results of its Annual Meeting of Shareholders

  4/12/2022

  Enzo Biochem, Inc. announced the approval of all proposals presented at its most recent Annual Meeting of Shareholders.

• Enzo Biochem Adjourns Annual Meeting of Shareholders Until April 8, 2022

  4/1/2022

  Enzo Biochem, Inc. today announced its 2021 Annual Meeting of Shareholders (“Annual Meeting”), with respect to Proposal 1, has been adjourned until April 8, 2022 at 9 AM EDT.